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FoBACKGROUND Fluorine-18–sodium ﬂuoride (18F-NaF) uptake is a marker of active vascular calciﬁcation associated with
high-risk atherosclerotic plaque.
OBJECTIVES In patients with abdominal aortic aneurysm (AAA), the authors assessed whether 18F-NaF positron
emission tomography (PET) and computed tomography (CT) predicts AAA growth and clinical outcomes.
METHODS In prospective case-control (n ¼ 20 per group) and longitudinal cohort (n ¼ 72) studies, patients with
AAA (aortic diameter >40 mm) and control subjects (aortic diameter <30 mm) underwent abdominal ultrasound,
18F-NaF PET-CT, CT angiography, and calcium scoring. Clinical endpoints were aneurysm expansion and the composite of
AAA repair or rupture.
RESULTS Fluorine-18-NaF uptake was increased in AAA compared with nonaneurysmal regions within the same
aorta (p ¼ 0.004) and aortas of control subjects (p ¼ 0.023). Histology and micro-PET-CT demonstrated that 18F-NaF
uptake localized to areas of aneurysm disease and active calciﬁcation. In 72 patients within the longitudinal cohort
study (mean age 73  7 years, 85% men, baseline aneurysm diameter 48.8  7.7 mm), there were 19 aneurysm
repairs (26.4%) and 3 ruptures (4.2%) after 510  196 days. Aneurysms in the highest tertile of 18F-NaF uptake
expanded 2.5 more rapidly than those in the lowest tertile (3.10 [interquartile range (IQR): 2.34 to 5.92 mm/year] vs.
1.24 [IQR: 0.52 to 2.92 mm/year]; p ¼ 0.008) and were nearly 3 as likely to experience AAA repair or rupture (15.3% vs.
5.6%; log-rank p ¼ 0.043).
CONCLUSIONS Fluorine-18-NaF PET-CT is a novel and promising approach to the identiﬁcation of disease
activity in patients with AAA and is an additive predictor of aneurysm growth and future clinical events. (Sodium
Fluoride Imaging of Abdominal Aortic Aneurysms [SoFIA3]; NCT02229006; Magnetic Resonance Imaging [MRI]
for Abdominal Aortic Aneurysms to Predict Rupture or Surgery: The MA3RS Trial; ISRCTN76413758) (J Am Coll Cardiol
2018;71:513–23) © 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
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514A bdominal aortic aneurysm (AAA)disease affects up to 5% of menaged 64 to 75 years, and its preva-
lence is increasing in more elderly popula-
tions (1). With progressive AAA expansion
over time, there is an increasing risk for
often fatal rupture, representing the 12th
commonest cause of death among older
men (2). Consequently, patients with AAA
enter an ultrasound-based surveillance pro-
gram, with the aim of facilitating pre-
emptive elective aneurysm repair to avoid
fatal rupture. AAA surveillance relies on se-
rial measurements of aneurysm diameter,
which is currently the best clinical predictor
of further expansion and rupture (3,4). How-
ever, AAA growth is nonlinear, unpredict-able, and inﬂuenced by biomechanical processes
that cannot be predicted by conventional anatomic
imaging alone (5). Indeed, aneurysms not infre-
quently rupture below the current threshold (55 mm
in diameter) for elective repair, and many patients
with aneurysms >70 mm never experience rupture
(6). There is therefore a need to develop more reliable
methods to identify patients who are at particular risk
for AAA expansion and rupture (7).SEE PAGE 524In AAA disease, degradation of the extracellular
matrix occurs in response to the accumulation of
inﬂammatory cells, such as macrophages and
lymphocytes, and the activation of matrix metal-
loproteinases. The resulting milieu of cellular
inﬂammation, tissue destruction, and necrosis can
lead to cycles of further inﬂammation (8). Focal
“hotspots” of such intense biological activity have
been identiﬁed in active aneurysm disease and can
occur at the site of rupture (9). We have recently
demonstrated that the positron-emitting radiotracer
18F–sodium ﬂuoride (18F-NaF) can identify areas of
early microcalciﬁcation (10) that occur in response to
necrotic inﬂammation in ruptured or high-risk hu-
man carotid (11) and coronary (12) atherosclerotic
plaques. This tracer has not been assessed in patients
with AAA, although loss of tissue integrity and
necrotic inﬂammation may be central to its patho-
physiology, underlie aneurysm expansion, andby the Academic Department of Military Surgery and Trauma.
/09/002, RE/13/3/30183, and RM/13/2/30158); and has receiv
AIA). The authors have reported that they have no relationship
received September 11, 2017; revised manuscript received Novemultimately predict disease progression and outcome
(7). We hypothesized that 18F-NaF uptake on positron
emission tomography (PET) would highlight areas of
microcalciﬁcation and AAA disease activity, repre-
senting regions prone to expansion and rupture. The
main aims of this study were to determine whether
18F-NaF uptake on combined PET and computed to-
mography (CT) is increased in AAA and whether this
is associated with aneurysm growth (the primary
endpoint) and subsequent rates of AAA repair or
rupture.
METHODS
STUDY POPULATION. Consecutive patients older
than 50 years under routine clinical surveillance
with asymptomatic AAA ($40 mm anteroposterior
diameter) were recruited from the MA3RS (Magnetic
Resonance Imaging in Abdominal Aortic Aneurysms to
Predict Rupture or Surgery) study (ISRCTN76413758)
database (13). Control subjects were recruited through
the National Health Service Lothian National
Abdominal Aortic Aneurysm Screening Programme or
the Vascular Laboratory at the Royal Inﬁrmary of
Edinburgh and had documented normal-caliber aortas
(<30-mm anteroposterior diameter).
STUDY DESIGN. This was a prospective single-
center, case-control, observational cohort study of
patients with asymptomatic AAA who were under
ultrasound-based surveillance as part of routine
clinical follow-up and control subjects with normal-
caliber abdominal aortas demonstrated on targeted
screening ultrasound. The study (NCT02229006)
was conducted with the written informed consent
of all subjects, with approval by the research ethics
committee, and in accordance with the Declaration
of Helsinki.
STUDY ASSESSMENTS. Participants underwent a
clinical evaluation including documentation of
medical history, concomitant medications, and family
history as well as an ultrasound evaluation of the
maximum anteroposterior abdominal aortic diameter.
Ultrasound scans were carried out in an accredited
clinical vascular science laboratory using a standard-
ized protocol with known interobserver variability of
3.4% (14). The AAA growth rate was determined using
the AAA maximum anteroposterior diameter obtainedDr. Newby is supported by the British Heart Foun-
ed a Wellcome Trust Senior Investigator Award
s relevant to the contents of this paper to disclose.
ber 6, 2017, accepted November 20, 2017.
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515at baseline and the last ultrasound examination per-
formed during study follow-up. Abdominal aortic tis-
sue was obtained at postmortem or from patients
undergoing elective AAA repair and analyzed by
micro–PET-CT and histology (Online Appendix).
18F-NaF PET-CT. Patients were administered a target
dose of 125 MBq of 18F-NaF intravenously and after
60 min were imaged on a hybrid 128–detector array
PET-CT scanner (Biograph mCT, Siemens Healthcare,
Erlangen, Germany) (10). A low-dose attenuation
correction CT scan was performed (120 kV, 50 mAs,
5/3 mm), followed by acquisition of PET data, using
3 10-min bed positions to ensure coverage from the
thoracic aorta to the aortic bifurcation. An
electrocardiographically gated calcium scoring
CT scan (120 kV, 120 mAs, 3/3 mm; prospective elec-
trocardiographic gating at 50% of the R-R interval)
and contrast-enhanced CT angiography (120 kV, 145
mAs, 3/3 mm, ﬁeld of view 400; and 1/1 mm, ﬁeld of
view 300; triggered at 181 Hounsﬁeld units) were
performed, centered on the AAA (or abdominal aorta
in control patients) and extending to the aortic
bifurcation (Figure 1).
To estimate 18F-NaF uptake, the maximum
standardized uptake values (SUVs) (a validated
measure of tissue radiotracer uptake) were quantiﬁed
from regions of interest (Online Appendix) (15).
Maximum tissue-to-background ratios (TBRs) were
then calculated, after correction for blood pool ac-
tivity using the averaged mean SUVs of 3 consecutive
regions of interest from the right atrium, according to
our previously described technique (16). Although
TBRmax was used for our primary analysis (12), we
also investigated other methods for quantiﬁcation,
including SUVmax and corrected SUVmax (calculated
by subtracting the blood pool activity from SUVmax)
(17). Finally, we adopted the “most diseased
segment” (MDS) approach, as suggested by others
(11,16,18–20). The MDS TBRmax was calculated as the
average TBRmax across 3 axial slices centered on
the region of the aneurysm with the highest tracer
activity (11).
CLINICAL ENDPOINTS AND ADJUDICATION. Clinical
data from clinic visits, the research database, elec-
tronic health records, primary care contacts, and the
General Register Ofﬁce were reviewed and clinical
endpoints adjudicated by the independent Clinical
Endpoint Committee (Online Appendix). The com-
mittee members were blinded to the ﬁndings of PET-
CT. Follow-up was censored at January 10, 2017, or at
the time of event.
STATISTICAL AND DATA ANALYSIS. Baseline char-
acteristics are reported as number (percentage) forcategorical variables and as mean  SD or median
(interquartile range) for continuous variables, as
appropriate. We stratiﬁed our patient cohort by AAA
MDS TBRmax tertiles to assess associations with
aneurysm expansion (the primary endpoint) and the
clinical outcomes of aneurysm repair or rupture (the
secondary endpoint). For the aneurysm growth and
outcomes analysis, AAA expansion rate and MDS
TBRmax were log-transformed (log2) to normalize the
data. One-way analysis of variance was used to
compare continuous data across multiple factors,
with post hoc analysis using the Bonferroni test as
appropriate. The Kruskal-Wallis test was used for
nonparametric continuous data and the log-rank test
for comparisons of AAA event rate and mortality be-
tween tertiles. Categorical data were compared using
chi-square or Fisher exact tests, and the unpaired
Student’s t-test was used to compare continuous
outcomes between 2 independent groups. Two-tailed
Pearson correlation and linear regression analysis
were performed to investigate the relationship be-
tween 18F-NaF uptake and aneurysm expansion.
Finally, we performed Kaplan-Meier and Cox regres-
sion analysis to investigate time to AAA event by
tertile, censored at the date of death. Statistical
analysis was undertaken using SPSS Statistics 23
(IBM, Armonk, New York), and signiﬁcance was taken
at the 2-sided 5% level (p < 0.05).
RESULTS
A total of 145 patients with AAA were screened for
inclusion: 136 were approached, and 76 patients ul-
timately attended for the scanning visit. Four pa-
tients underwent protocol development scans, had
incomplete data, and were excluded from the ﬁnal
analysis, leaving a total of 72 patients with AAA and
20 control subjects (Figure 2). Patients were pre-
dominantly elderly (mean age 72.5  6.9 years) men
(84.7%) with multiple cardiovascular risk factors,
including hypertension (65.3%) and hypercholester-
olemia (81.9%) (Table 1). More than 90% were cur-
rent or ex-smokers (27.8% and 65.3%, respectively),
with a mean baseline AAA diameter of 48.8 
7.7 mm. Control subjects were younger (mean age
65.2  2.8 years) but also predominantly men
(95.0%), and 40% were current (25%) or prior (15%)
smokers.
CASE-CONTROL STUDY. Twenty patients with AAA
were matched for age, sex, and smoking status with
the 20 control subjects (Table 1). Background blood
pool activity in the right atrium was similar between
groups (log2 SUVmean 0.570  0.517 vs. 0.588 
0.531; difference 0.018; 95% conﬁdence interval
FIGURE 1 Positron Emission Tomographic and Computed Tomographic Images of Abdominal Aortic Aneurysms
(A) Structural image of computed tomographic angiography, (B) 18F–sodium ﬂuoride uptake on positron emission tomography, and (C) fused positron
emission tomographic–computed tomographic images colocalizing 18F–sodium ﬂuoride uptake with the skeleton and abdominal aortic aneurysm.
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FIGURE 2 Study Populations
Patients with AAA Screened
145
Major illness, 4
Contraindication to scan, 2
Planned surgery, 3
Ineligible Patients, 9
Major illness, 7
Contraindication to scan, 2
Ineligible Volunteers, 9
Declined, 37
Unable to contact, 16
Non-recruited Eligible Volunteers, 53
Unable to tolerate PET-CT, 0
Withdrawn, 0
Declined, 53
Unable to contact, 6
Non-recruited Eligible Patients, 59
Unable to tolerate PET-CT, 1
Withdrawn, 1
Protocol development scans, 4
Scans Not Analyzed, 4
Patients with AAA Control Volunteers
Control Volunteers Screened
82
Eligible Volunteers
73
Consented Volunteers
20
Study Population
20
Eligible Patients
136
Consented Patients
77
Study Population
76
Observational Cohort
Population
72
The 20 patients for the case-control study were selected from within the cohort study population. AAA ¼ abdominal aortic aneurysm; CT ¼ computed tomography;
PET ¼ positron emission tomography.
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517[CI]: 0.340 to 0.376; p ¼ 0.919). Fluorine-18-NaF
uptake was higher in the AAA when compared with
the abdominal aorta of control subjects irrespective of
the method of quantiﬁcation (e.g., log2 MDS TBRmax
1.712  0.560 vs. 1.314  0.489; difference 0.398;
95% CI: 0.057 to 0.739; p ¼ 0.023) (Online Table 1).
In contrast to control aortic tissue, AAA tissue
demonstrated ex vivo 18F-NaF uptake that correlated
with areas of tissue disruption with necrotic debris
and active calciﬁcation (r ¼ 0.808, p ¼ 0.015)
(Figure 3). Areas of 18F-NaF uptake on PET were
distinct from areas of macrocalciﬁcation on CT
(Online Video 1).
Patients with AAA had more cardiovascular risk
factors and higher abdominal aortic CT calcium scores
(log2 Agatston score 11.444  1.760 vs. 7.338  3.811;
difference 4.105; 95% CI: 2.013 to 6.198; p ¼ 0.001)
(Online Table 1) than control subjects. However, no
differences in 18F-NaF uptake were observed between
these groups in either the descending thoracic aorta
or the nonaneurysmal abdominal aorta.OBSERVATIONAL COHORT STUDY. Fluorine-18-NaF
uptake was again higher in the aneurysm than in
the nonaneurysmal portion of the abdominal aorta
(log2 TBRmax 1.647  0.537 vs. 1.332  0.497; differ-
ence 0.314; 95% CI: 0.0685 to 0.560; p ¼ 0.004) and
almost double the uptake observed in the descending
thoracic aorta (log2 TBRmax 1.647  0.537 vs. 0.881 
0.414; difference 0.766; 95% CI: 0.517 to 1.011;
p < 0.0001). These differences were consistently
observed regardless of the method of PET
quantiﬁcation.
Across the tertiles of AAA MDS TBRmax, there were
no differences in most risk factors for AAA disease,
including age, sex, smoking habit, aneurysm diam-
eter, hypertension, and hypercholesterolemia.
Although there appeared to be some differences with
respect to diastolic blood pressure, body mass index,
and peripheral arterial disease, the trend was incon-
sistent across the tertiles (Table 1).
18F-NaF UPTAKE AND ANEURYSM GROWTH. During
510  196 days of follow-up, the median AAA
TABLE 1 Characteristics of Study Participants
Cohort Study Case-Control Study
All Patients With AAA
(N ¼ 72)
Tertile 1
(n ¼ 24)
Tertile 2
(n ¼ 24)
Tertile 3
(n ¼ 24) p Value*
Patients With AAA
(n ¼ 20)
Control Subjects
(n ¼ 20)
Characteristics
Age, yrs 72.5  6.9 73.3  7.2 72.8  7.5 71.4  6.1 0.640 66.2  2.6 65.2  2.8
Male 61 (84.7) 20 (83.3) 21 (85.7) 20 (83.3) 1.000 19 (95.0) 19 (95.0)
Systolic blood pressure, mm Hg 136.7  18.3 142.1  18.2 132.5  16.2 135.6  19.9 0.178 138.1  22.5 141.6  14.2
Diastolic blood pressure, mm Hg 81.6  11.6 84.8  12.0 76.4  9.4 83.5  11.9 0.024 84.2  16.6 80.5  8.2
Heart rate, beats/min 71  9 72  10 70  8 70  8 0.694 70.2  9.7 66.7  13.5
Body mass index, kg/m2 27.6  3.5 27.6  3.4 26.2  3.3 29.0  3.3 0.019 28.4  3.1 29.3  6.4
Current smoker 20 (27.8) 6 (25.0) 9 (37.5) 5 (20.8) 0.407 5 (25.0) 5 (25.0)
Medical history
Hypertension 47 (65.3) 14 (58.3) 16 (66.7) 17 (70.8) 0.651 12 (60.0) 6 (30.0)
Hypercholesterolemia 59 (81.9) 21 (87.5) 21 (87.5) 17 (70.8) 0.264 15 (75.0) 7 (35.0)
Diabetes 10 (13.9) 3 (12.5) 4 (16.7) 3 (12.5) 1.000 1 (5.0) 2 (10.0)
Ischemic heart disease 22 (30.6) 7 (29.2) 7 (29.2) 8 (33.3) 0.937 5 (25.0) 1 (5.0)
Peripheral arterial disease 11 (15.3) 2 (8.3) 8 (33.3) 1 (4.2) 0.021 2 (10.0) 1 (5.0)
Cerebrovascular disease 10 (13.9) 1 (4.2) 4 (16.7) 5 (20.8) 0.316 1 (5.0) 0 (0.0)
Positive family history of AAA 9 (12.5) 2 (8.3) 4 (16.7) 3 (12.5) 0.903 3 (15.0) 2 (10.0)
Medications
Antiplatelet agents 51 (70.8) 19 (79.2) 18 (75.0) 14 (58.3) 0.350 11 (55.0) 3 (15.0)
Statins 58 (80.6) 21 (87.5) 21 (87.5) 16 (66.7) 0.141 13 (65.0) 8 (40.0)
Anticoagulant agents 2 (2.8) 1 (4.2) 0 (0.0) 1 (4.2) 1.000 0 (0.0) 1 (5.0)
Beta-blockers 19 (26.4) 8 (33.3) 5 (20.8) 6 (25.0) 0.711 6 (30.0) 2 (10.0)
ACE inhibitors 25 (34.7) 8 (33.3) 8 (33.3) 9 (37.5) 1.000 5 (25.0) 2 (10.0)
Aorta
Aortic diameter, mm 48.8  7.7 47.5  9.2 48.7  7.8 50.1  5.8 0.510 45.7  4.0 17.6  2.3
Concurrent iliac aneurysm 13 (18.1) 4 (16.7) 5 (20.8) 4 (16.7) 1.000 3 (15.0) 0.0 (0.0)
Values are mean  SD or n (%). *p value for trend across the tertiles.
AAA ¼ abdominal aortic aneurysm; ACE ¼ angiotensin-converting enzyme; 18F-NaF ¼ 18F–sodium ﬂuoride.
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518expansion rate was 2.20 mm/year (interquartile
range: 0.96 to 3.72 mm/year) (Table 2). Baseline 18F-
NaF activity in the aneurysm was associated with
future expansion regardless of the method of quan-
tiﬁcation (e.g., log2 MDS TBRmax r ¼ 0.365; p ¼ 0.006).
When stratiﬁed by tertiles, aneurysms in the highest
tertile expanded 2.5 more rapidly than those in the
lowest tertile (3.10 mm/year [IQR: 2.34 to 5.92 mm/
year] vs. 1.24 mm/year [IQR: 0.52 to 2.92 mm/year];
p ¼ 0.008) (Figure 4). Moreover, in multivariate
analysis, 18F-NaF activity in the AAA (MDS TBRmax)
emerged as a predictor of growth independent of age,
sex, baseline diameter, body mass index, blood
pressure, smoking, renal function, or peripheral
arterial disease (p ¼ 0.042) (Online Table 2). In
contrast, the aneurysm Agatston score was not asso-
ciated with future expansion (r ¼ 0.199; p ¼ 0.141).
18F-NaF UPTAKE AND CLINICAL EVENTS. In total, 22
patients (30.6%) met the composite endpoint of AAA
repair or rupture. Of these, 19 (26.4%) underwent
elective AAA repair and 3 (4.2%) experienced AAArupture, all of whom died without repair. Five other
patients died during study follow-up, all from non-
AAA causes.
Patients with aneurysms in the highest tertile of
18F-NaF uptake were more likely to experience AAA
repair or rupture during follow-up (15.3% vs. 5.6%;
log-rank p ¼ 0.043) (Table 2). They also had a reduced
time to AAA event: 572 days versus 735 days for AAA
repair (log-rank p ¼ 0.014) and 572 days versus
709 days for the composite of AAA repair or rupture
(log-rank p ¼ 0.043) (Figure 4). In those patients who
experienced AAA events, 18F-NaF activity was higher
than in those who continued under surveillance
without events (log2 MDS TBRmax 2.20  0.58 vs. 1.87
 0.54; difference 0.330; 95% CI: 0.047 to 0.613;
p ¼ 0.023). In unadjusted analysis, a doubling of 18F-
NaF activity in the MDS was associated with a more
than 2-fold risk for experiencing AAA rupture or
repair (hazard ratio: 2.16; 95% CI: 1.03 to 4.50;
p ¼ 0.041) (Table 2). When adjusted for age, sex,
baseline diameter, systolic blood pressure, body mass
FIGURE 3 Correlation of Histology With Micro–Positron Emission Tomography and Computed Tomography of Abdominal Aortic Tissue
Ex vivo micro–positron emission tomography and computed tomography (left) and histology (right) of aortic wall excised (A) at postmortem
in a patient without an aneurysm and (B) during open abdominal aortic aneurysm repair. Regions of interest (dashed circle) of 18F–sodium
ﬂuoride (18F-NaF) uptake demonstrate atheromatous disease with necrosis (hematoxylin and eosin stain, magniﬁcation 100 [Online Video 1];
B1) and calciﬁcation (black, Von Kossa stain, magniﬁcation 200; B2) in the aortic aneurysm tissue that is not apparent in control aorta
(A1, A2).
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TABLE 2 Expansion Rate and Clinical Outcomes According to Tertiles of 18F–Sodium
Fluoride Uptake
Outcome
All Patients
With AAA
(N ¼ 72)
Tertile 1
(n ¼ 24)
Tertile 2
(n ¼ 24)
Tertile 3
(n ¼ 24) p Value*
AAA expansion
rate, mm/yr
2.20
(0.96–3.73)
1.24
(0.52–2.92)
1.55
(0.81–3.12)
3.10
(2.34–5.92)
0.008
AAA events
Composite events 22 (30.6) 4 (16.7) 7 (29.2) 11 (45.8) 0.043
Repair 19 (26.4) 3 (12.5) 5 (20.8) 11 (45.8) 0.014
Rupture 3 (4.2) 1 (4.2) 2 (8.3) 0 (0.0)
Deaths
All-cause 8 (11.1) 4 (16.7) 4 (16.7) 0 (0.0) 0.343
AAA-related 3 (4.2) 1 (4.2) 2 (8.3) 0 (0.0) —
Values are median (interquartile range) or n (%). *p value for trend across the tertiles.
AAA ¼ abdominal aortic aneurysm.
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520index, and smoking, this risk remained (hazard ratio:
2.49; 95% CI: 1.07 to 5.78; p ¼ 0.034) (Online Table 2).
DISCUSSION
In this prospective series of clinical studies, we have
demonstrated for the ﬁrst time that 18F-NaF uptake is
speciﬁcally increased in AAA and relates to areas of
advanced aneurysmal disease. Moreover, 18F-NaF
uptake is a major predictor of aneurysm expansion
and clinical outcome that is additive to standard
clinical risk factors, including aneurysm diameter.
This is the ﬁrst study to demonstrate that an imaging
biomarker of disease activity can add to the risk
prediction of AAA and to suggest that this approach
might reﬁne clinical decisions regarding the need for
surgery and improve patient outcomes (Central
Illustration).
Our studies have several major strengths and
prominent observations. First, we have shown AAA
tissue demonstrates markedly increased levels of 18F-
NaF uptake that far exceed those seen in control
volunteers. Perhaps more important, uptake of the
AAA also exceeds that observed in the non-
aneurysmal aorta within the same patient. Second,
we demonstrate that 18F-NaF uptake localized to
areas of AAA disease, highlighting diseased areas of
poor tissue integrity that may be susceptible to
aneurysm expansion and clinical events. Third, we
assessed the potential clinical value of this technique
in a cohort of patients with extended follow-up in
which the clinicians responsible for the patient’s care
were unaware of the ﬁndings of PET-CT. It is there-
fore salient to note that 18F-NaF uptake predicted
expansion and clinical outcomes in addition to clin-
ical risk factors including AAA diameter, especially as
the latter drives the decision for elective AAA repair.Fourth, this is the largest dedicated study using PET-
CT in AAA disease to date and the ﬁrst clinical study
to investigate 18F-NaF PET-CT in AAA disease pro-
gression (21). Finally, this was a prospective clinical
cohort study, in contrast with many previous studies
of PET-CT in patients with AAA that are based on
retrospective data, often obtained from cohorts
derived from oncological imaging practice.
We previously demonstrated that 18F-NaF selec-
tively binds to microcalciﬁcation in coronary (11) and
carotid atherosclerotic (10,11) plaques and that this is
associated with plaque vulnerability and rupture. We
(11,12) and others (22) have also shown that 18F-NaF
binds to areas of tissue necrosis–associated myocar-
dial and cerebral infarction. In our present study, data
from histology and micro–PET-CT indicate that this
tracer behaves in a similar fashion in AAA. Increased
18F-NaF uptake was most marked in AAA tissue with
advanced disease and active calciﬁcation. We suggest
that 18F-NaF uptake again relates to micro-
calciﬁcation and is particular to the most diseased
areas associated with tissue disruption and loss of
integrity. Interestingly, we also showed that 18F-NaF
was distinct from AAA macrocalciﬁcation detected by
CT and that the latter is not associated with expan-
sion or AAA events, suggesting that once established,
dense calciﬁed deposits represent a more stabilized
biological state.
Most previous clinical studies using PET-CT in AAA
disease have focused on the use of 18F-ﬂuorodeox-
yglucose (FDG) to identify inﬂammation, with vari-
able results and no clear clinical application.
Although some groups have suggested a potential
role for 18F-FDG PET-CT in predicting AAA expansion
or rupture (23–25), others have disputed this and re-
ported contradictory ﬁndings (26,27). This in part re-
lates to the small study sample sizes and whether
patients had symptomatic or inﬂammatory AAAs, but
to date there is no clear relationship between 18F-FDG
and aneurysm expansion or clinical outcome (22). Our
present study was nested within another larger clin-
ical cohort study, the MA3RS trial. This was a multi-
center study of 342 patients with AAA who
underwent ultrasmall superparamagnetic particles of
iron oxide (USPIO)–enhanced magnetic resonance
imaging to identify cellular inﬂammation within the
aortic wall (13). This study recently reported and
demonstrated that although USPIO-enhanced mag-
netic resonance imaging did predict AAA expansion
and clinical outcome, the association was modest and
was not independent of established clinical factors,
including ultrasound AAA diameter (28). This sug-
gests that imaging of cellular inﬂammation alone,
either by 18F-FDG or USPIO-enhanced magnetic
FIGURE 4 Prediction of Disease Progression and Clinical Outcome by 18F–Sodium
Fluoride Positron Emission Tomography
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Association of 18F–sodium ﬂuoride (18F-NaF) uptake with disease progression and clinical
outcome. (A) Rate of aneurysm expansion (millimeters per year, log2 transformed)
across the tertiles of 18F-NaF uptake. The highest tertile expanded more rapidly than
those in the lowest tertile (3.10 vs. 1.24 mm/year, respectively, p ¼ 0.008). Cumulative
event rate (censored at date of death) across the tertiles of 18F-NaF uptake for (B)
abdominal aortic aneurysm repair or rupture (log-rank p ¼ 0.043) and (C) abdominal
aortic aneurysm repair (log-rank p ¼ 0.014).
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521resonance imaging, is insufﬁcient to provide additive
clinical information beyond established clinical risk
factors and AAA diameter. In contrast, 18F-NaF PET-
CT identiﬁes focal areas of microcalciﬁcation indica-
tive of more advanced aneurysm disease and
independently predicts both disease progression and
clinical events.
We have demonstrated an important clinical
application of 18F-NaF PET-CT in AAA disease. Until
now, future prediction of aneurysm expansion has
relied on the simple morphological parameter of
aneurysm diameter. However, it is clear that AAA
growth is nonlinear and cannot be predicted accu-
rately from a simple anatomic measure, such as AAA
diameter. Although we know that larger aneurysms
tend to expand more rapidly and are more prone to
rupture, disease evolution is not straightforward.
Better AAA disease prediction using 18F-NaF uptake
could be particularly useful for patients in whom the
decision to intervene is challenging, such as those
with high-risk aneurysms smaller than 55 mm, those
with borderline aneurysm sizes, and those with larger
aneurysms where the balance of risk and beneﬁt is
uncertain.
STUDY LIMITATIONS. This was a single-center proof-
of-concept study with a small number of rupture
events, making adjustment for potential confounders
and covariates challenging. Although we observed no
marked differences in sex across the tertiles of 18F-
NaF uptake, our study population had a strong male
bias (typical of this disease population), and we
cannot be certain that our ﬁndings are truly repre-
sentative of both men and women. The clinical
impact of this technique has not been assessed and
would require a larger trial in which clinical and
surgical decisions would be inﬂuenced or dictated by
the ﬁndings of 18F-NaF PET-CT. The widespread
implementation of this technique may be chal-
lenging, especially given the relative expense and
complexity of PET-CT compared with ultrasound.
However, we have demonstrated the feasibility of
this technique, which uses a well-established, widely
available, and relatively cheap radiotracer. Moreover,
with the more widespread use and availability of
PET-CT scanners, barriers to implementation are
declining. There are also some inherent limitations of
18F-NaF image analysis that merit comment. Being a
bone tracer, 18F-NaF is readily taken up by the
vertebrae, which lie in close proximity to the
abdominal aorta. In our study, it was necessary to
exclude some areas of the posterior aorta because of
overspill of signal. However, this is not unique to 18F-
NaF, with similar issues seen with 18F-FDG uptake in
CENTRAL ILLUSTRATION Fluorine-18–Sodium Fluoride Uptake in Abdominal Aortic Aneurysms
Forsythe, R.O. et al. J Am Coll Cardiol. 2018;71(5):513–23.
Fluorine-18–sodium ﬂuoride uptake is speciﬁc to abdominal aortic aneurysm tissue, is proportional to the rate of aneurysm expansion, and predicts the risk for repair or
rupture independent of aneurysm diameter.
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522regions of interest adjacent to bowel, muscle, or other
metabolically active tissues. Finally, further valida-
tion of the tissue binding characteristics and time
course of change in 18F-NaF uptake in aneurysmal
and nonaneurysmal aortas are needed, and this
would be interesting to explore in future studies.
CONCLUSIONS
This novel proof-of-concept PET-CT study of patients
with asymptomatic AAA demonstrates that 18F-NaF
uptake identiﬁes advanced aneurysmal disease and is
associated with aneurysm growth and clinical AAA
events independent of established clinical riskfactors, including aneurysm diameter. This technique
holds major promise for the future management of
patients with AAA disease.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
18F-Sodium ﬂuoride uptake is speciﬁc to abdominal
aortic aneurysm tissue, proportional to the rate of
aneurysm expansion, and predictive of repair or
rupture, independent of aneurysm diameter.
TRANSLATIONAL OUTLOOK: Additional studies are
needed to clarify the clinical utility of this imaging
biomarker as a guide to selection of patients for
elective repair of abdominal aortic aneurysms.
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